Indoco Remedies Limited has scheduled its 79th Annual General Meeting (AGM) for Thursday, September 17, 2026, at 10:30 am. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) in compliance with the Companies Act, 2013, and SEBI Listing Regulations.

The Board of Directors, in its meeting on May 7, 2026, recommended a final dividend of ₹0.20 per equity share of face value ₹2 each for the financial year ended March 31, 2026. This payout is subject to approval by shareholders at the AGM. If approved, the dividend will be paid electronically within 30 days of the meeting date.

Key Dates and Dividend Details

The record date for determining dividend entitlement is set for Thursday, September 10, 2026. Consequently, the Register of Members and Share Transfer Books will remain closed from Friday, September 11, 2026, to Thursday, September 17, 2026, inclusive.

Participation and Voting

Shareholders can participate in the AGM via VC/OAVM facilities provided by the Registrar and Transfer Agent, MUFG Intime India Private Limited. The Notice of the AGM and the Annual Report for FY26 are available electronically on the company’s website and stock exchange portals. Physical copies are not being dispatched as per MCA Circular No. 03/2025.

Voting will be conducted through e-voting. Members holding shares in physical or dematerialized mode can cast their votes remotely. Those who have not registered email addresses with the company or their Depository Participants must update their details via Form ISR-1 or contact their DP respectively to enable remote voting and electronic dividend receipt.

Dividend payments will be made only through electronic modes where bank account details are available. For physical shareholders, payment is contingent upon furnishing PAN, contact details, and bank information. Tax at source (TDS) will be deducted as per the Income-tax Act, 2025.

Indoco Remedies Limited reported a standalone revenue growth of 5.8% year-on-year to ₹4,081 million for the quarter ended June 30, 2026, driven by resilient domestic formulation sales and strong performance in its API business. During the earnings conference call held on July 28, 2026, management emphasized a strategic shift towards debt reduction and operational efficiency, having lowered total debt to ₹930 crore from ₹964 crore as of March 2026. The company aims for double-digit EBITDA margins in the current financial year, leveraging cost optimizations and a focused portfolio of high-margin brands despite temporary headwinds in international regulated markets.

Managing Director Aditi Panandikar attributed the revenue growth to steady execution across core domestic formulations, regulated international markets, and the vertically integrated API platform. Consolidated revenue reached ₹4,662 million, up 8.2% year-on-year. Standalone EBITDA expanded to ₹422 million, delivering an EBITDA margin of 10.3%, compared to 3.8% in the same quarter last year. The Board of Directors approved the unaudited financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Operational Highlights

Domestic formulations contributed ₹2,040 million to quarterly revenue, maintaining Indoco’s position as the 33rd largest player in the Indian pharma market based on IQVIA MAT June 2026 data. The top five flagship brands now contribute 42% to the total domestic portfolio. Cyclopam emerged as a key growth driver, achieving 44% absolute growth since 2022 to reach ₹196 crore, nearing the landmark ₹200 crore milestone. Midsized brands such as SM Fibro, Rexidin-M, Oxipod CV, and Dropizin recorded an aggregate growth of 86%, with Dropizin tripling its revenue to ₹14 crore.

Internationally, the active pharmaceutical ingredients (API) business surged 42.4% year-on-year to ₹521 million, providing crucial backward integration for the formulations pipeline. International formulations revenue grew 2.8% to ₹1,451 million, with regulated markets contributing significantly. Revenues from the U.S. business jumped 62.2% to ₹459 million, while Europe grew 2.5% to ₹650 million. However, emerging markets saw a decline to ₹317 million from ₹461 million, which management described as a temporary fluctuation due to primary billing timing and supply chain constraints.

Key Financial Metrics

*Net profit figures include exceptional gains from the slump sale of the Ophthalmic Business Division.

Debt Reduction and Capital Allocation

Chief Financial Officer Pramod Ghorpade detailed the company’s improved balance sheet, noting that long-term debt stands at ₹600 crore and short-term debt at approximately ₹325 crore. The company has committed to repaying ₹110 crore in the current fiscal year and another ₹150 crore in the next, totaling ₹260 crore over the next 7 to 18 months. Proceeds from the ophthalmic division sale and potential land parcel disposals are being utilized to accelerate this repayment schedule. The average interest cost on the overall debt is approximately ₹20.5 crore per quarter at an effective rate of 9%.

What the Numbers Show

The divergence between operational profitability and headline net profit remains a critical focus area. While standalone EBITDA margins expanded significantly to 10.3%, core operations still face pressure from gross margin erosion due to increased cost of goods sold (COGS). Management cited a 2 percentage point impact on gross margins from higher raw material costs linked to geopolitical tensions, which is expected to partially persist into Q2FY27. However, structural efficiency gains from the Master Manufacturing Plan have reduced batch counts by 26% while maintaining output, leading to a reduction of nearly 900 employees in operations. This suggests that while input costs remain volatile, operating leverage is improving through fixed-cost optimization rather than pure volume growth.

Regulatory clarity remains the primary catalyst for international growth. The Baddi Unit I and III facilities hold EU-GMP certifications, but the U.S. sterile business awaits a pending USFDA audit, which has delayed new product approvals. Management indicated that once cleared, the U.S. sterile segment could unlock significant value, particularly for products like brimonidine and dorzolamide. Until then, the company is focusing on scaling oral solids in the U.S. and expanding its footprint in Europe, where it currently holds an order book exceeding ₹250 crore.